Resistance to HER2-targeted therapies: a potential role for FOXM1.
about
Gastric cancer: The times they are a-changin'Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling.FoxM1 is a promising candidate target in the treatment of breast cancer.Targeting Forkhead Box M1 Transcription Factor in Breast Cancer.Cancer panel analysis of circulating tumor cells in patients with breast cancer.
P2860
Resistance to HER2-targeted therapies: a potential role for FOXM1.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@ast
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@en
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@nl
type
label
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@ast
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@en
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@nl
prefLabel
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@ast
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@en
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@nl
P2860
P356
P1476
Resistance to HER2-targeted therapies: a potential role for FOXM1.
@en
P2093
Bridgette F Peake
Rita Nahta
P2860
P304
P356
10.2217/BMT.14.33
P577
2014-01-01T00:00:00Z